Start:
July 30, 2018
End:
August 2022
Enrollment:
70
In a process known as clearance, cerebrospinal fluid carries waste products from the brain to the bloodstream. This study will use positron emission tomography (PET) scanning to examine whether impaired clearance of amyloid protein from the brain causes amyloid to build up in the brain and increase the risk for Alzheimer's disease. Researchers will collect positron emission tracer (PET) scans to measure the amount of two proteins, amyloid and tau, in the brain. Participants will also undergo a lumbar puncture and an MRI brain scan to assess any changes in brain structure.
Minimum Age: 40 Years
Maximum Age: 100 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: New York University School of Medicine
Source: ClinicalTrials.gov ID: NCT03663387
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health